Components Qualification for a Possible use in the Mu2e Calorimeter Waveform Digitizers

The Mu2e experiment at Fermilab searches for the charged flavor violating conversion of a muon into an electron in the Coulomb field of a nucleus. The detector consists of a straw tube tracker and a CSI crystal electromagnetic calorimeter, both housed in a superconducting solenoid. Both the front-end and the digital electronics, located inside the cryostat, will be operated in vacuum under a 1 T magnetic field, having to sustain the high flux of neutrons and ionizing particles coming from the muons stopping target. These harsh experimental conditions make the design of the calorimeter waveform digitizer quite challenging. All the selected commercial devices must be tested individually and qualified for radiation hardness and operation in high magnetic field. At the moment the expected particles flux and spectra at the digitizers location are not completely simulated and we are using initial rough estimates to select the components for the first prototype. We are gaining experience in the qualification procedures using the selected components but the choice will be frozen only when dose and neutron flux simulations will be completed. The experimental results of the first qualification campaign are presented.Comment: TWEPP 2016 - Topical Workshop on Electronics for Particle Physics, 26-30 September 2016, Karlsruhe Institute of Technology (KIT

Low-dose interleukin-2 for treating postautologous transplant cytogenetic abnormality recurrency in a case of acute myeloid leukemia with hyperdiploidy.

Adoptive immunotherapy and/or immunostimulation may be effective in treating early phases of leukemia relapsing after allogeneic transplant. Donor lymphocyte infusion (DLI) is an established treatment for cytogenetic relapse of chronic myeloid leukemia (CML) after unmanipulated or T-cell–depleted bone marrow transplant (BMT)1; favorable results have also been reported in a few cases of initial posttransplant relapse of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).2 A graft-versus-leukemia (GVL) effect as part of a manifest or occult DLI-elicited graft-versus-host disease (GVHD) is thought to be the reason for these favorable results. For patients who had received autologous transplant, attempts to elicit an antineoplastic effect by immunostimulation have been made using in vitro interleukin-2 (IL-2)–activated autologous lymphocytes and/or IL-2 in vivo administration.34 We report on the successful use of subcutaneous (sc) low-dose IL-2 in a patient suffering from AML with recurrence of cytogenetic abnormalities after autografting

CD34+ enriched donor lymphocyte infusions in a case of pure red cell aplasia and late graft failure after major ABO-incompatible bone marrow transplantation

A variety of immunohematological complications may occur after ABO-incompatible BMT. We report a CML patient (blood group O) who received a BMT from an HLA-identical sibling (blood group AB). The transplant was followed by normal myeloid and megakaryocytic engraftment, but erythroblastopenia persisted for more than 200 days after BMT. By bone marrow culture studies, a complement-dependent serum inhibitor of hemopoiesis was detected, suggesting immunological inhibition of erythropoiesis. The patient was resistant to a number of treatments such as intravenous gamma-globulins, prednisolone and high-dose erythropoietin. Full engraftment with normal blood counts and marrow cellularity was achieved after two dose-escalating CD34+-enriched donor lymphocyte infusions (DLI). This experience suggests that CD34+-enriched DLI may be an effective treatment for patients with delayed engraftment or late graft failure due to major ABO-incompatibility

The economic impact of sight loss and blindness in the UK adult population

Background: To quantify the economic impact of sight loss and blindness in the United Kingdom (UK) population, including direct and indirect costs, and its burden on health. Methods: Prevalence data on sight loss and blindness by condition, Census demographic data, data on indirect costs, and healthcare cost databases were used. Blindness was defined as best corrected visual acuity (BCVA) of < 6/60, and sight loss as BCVA < 6/12 to 6/60, in the better-seeing eye. Results: Sight loss and blindness from age-related macular degeneration (AMD), cataract, diabetic retinopathy, glaucoma and under-corrected refractive error are estimated to affect 1.93 (1.58 to 2.31) million people in the UK. Direct health care system costs were £3.0 billion, with inpatient and day care costs comprising £735 million (24.6%) and outpatient costs comprising £771 million (25.8%). Indirect costs amounted to £5.65 (5.12 to 6.22) billion. The value of the loss of healthy life associated with sight loss and blindness was estimated to be £19.5 (15.9 to 23.3) billion or £7.2 (5.9 to 8.6) billion, depending on the set of disability weights used. For comparison with other published results using 2004 disability weights and the 2008 estimates, the total economic cost of sight loss and blindness was estimated to be £28.1 (24.0 to 32.5) billion in 2013. Using 2010 disability weights, the estimated economic cost of sight loss and blindness was estimated to be £15.8 (13.5 to 18.3) billion in 2013. Conclusions: The large prevalence of sight loss and blindness in the UK population imposes significant costs on public funds, private expenditure, and health. Prevalence estimates relied on dated epidemiological studies and may not capture recent advances in treatment, highlighting the need for population-based studies that track the prevalence of sight-impairing eye conditions and treatment effects over time

Energy and time resolution for a LYSO matrix prototype of the Mu2e experiment

We have measured the performances of a LYSO crystal matrix prototype tested with electron and photon beams in the energy range 60$-$450 MeV. This study has been carried out to determine the achievable energy and time resolutions for the calorimeter of the Mu2e experiment.Comment: 2 pages, 3 figures, 13th Pisa Meeting on Advanced Detector

Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018

BACKGROUNDS AND AIMS: Non-alcoholic steatohepatitis (NASH) – a progressive subset of non-alcoholic fatty liver disease (NAFLD) – is a chronic liver disease that can progress to advanced fibrosis, cirrhosis, and end-stage liver disease (ESLD) if left untreated. Early-stage NASH is usually asymptomatic, meaning a large proportion of the prevalent population are undiagnosed. Receiving a NASH diagnosis increases the probability that a patient will receive interventions for the purpose of managing their condition. The purpose of this study was to estimate the disease burden and economic impact of diagnosed NASH in the United Kingdom (UK) adult population in 2018. METHODS: The socioeconomic burden of diagnosed NASH from a societal perspective was estimated using cost-of-illness methodology applying a prevalence approach. This involved estimating the number of adults with diagnosed NASH in the UK in a base period (2018) and the economic and wellbeing costs attributable to diagnosed NASH in that period. The analysis was based on a targeted review of the scientific literature, existing databases and consultation with clinical experts, health economists and patient groups. RESULTS: Of the prevalent NASH population in the UK in 2018, an estimated 79.8% were not diagnosed. In particular, of the prevalent population in disease stages F0 to F2, only 2.0% (F0), 2.0% (F1) and 16.5% (F2), respectively, were diagnosed. Total economic costs of diagnosed NASH in the UK ranged from £2.3 billion (lower prevalence scenario, base probability of diagnosis scenario) to £4.2 billion (higher prevalence scenario, base probability of diagnosis scenario). In 2018, people with NASH in the UK were estimated to experience 94,094 to 174,564 disability-adjusted life years (DALYs) overall. Total wellbeing costs associated with NASH in 2018 were estimated to range between £5.6 to £10.5 billion. CONCLUSIONS: The prevention and appropriate management of adult NASH patients could result in reduced economic costs and improvements in wellbeing